Market research
TBF1.F Canntab Therapeutics Limited
F EUR Not available
Latest close
Loading market data…
Test a moving-average rule with historical data.
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.86
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Not available
- Industry
- Not available
- ISIN
- CA1377991023
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 1.86
About
About Canntab Therapeutics Limited
Canntab Therapeutics Limited, a phytopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TBF1.F discussion.
5 years, 5 months ago
Canntab Therapeutics Limited is currently in a long term downtrend where the price is trading 1.8% below its 200 day moving average.
From a valuation standpoint, the stock is 93.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 86.6.
Canntab Therapeutics Limited's total revenue rose by inf% to $378K since the same quarter in the previous year.
Its net income has increased by 2.1% to $-610K since the same quarter in the previous year.
Finally, its free cash flow fell by 43.3% to $-585K since the same quarter in the previous year.
Based on the above factors, Canntab Therapeutics Limited gets an overall score of 3/5.